Day: March 11, 2024

SANTA PAULA, Calif., March 11, 2024 (GLOBE NEWSWIRE) — Calavo Growers, Inc. (Nasdaq-GS: CVGW), a global avocado industry leader and provider of convenient, ready-to-eat fresh food, today reported its financial results for the fiscal first quarter ended January 31, 2024. First Quarter Financial Overview Introductory Note: In the first quarter of 2024, we concluded that the fresh cut (formerly RFG) business meets the requirements to be classified as held for sale and discontinued operations. As a result, the financial results of that business are reported as discontinued operations in this press release. Prior to the decision to divest our fresh cut business, the Company’s Prepared reporting segment included the fresh cut business unit and our guacamole business. Due to the planned divestiture, the fresh cut business unit is no longer...

SHAKOPEE, Minn., March 11, 2024 (GLOBE NEWSWIRE) — Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (Nasdaq: CPHC) today reported financial results for the fourth quarter and full year ended December 31, 2023.   ($ in thousands, except per share data and percentages)   Three Months Ended December 31,   Twelve Months Ended December 31,  2023   2022   Change   2023   2022   ChangeNet revenues $12,527     $13,119     -4.5 %   $61,437     $66,824     -8.1 %                                   Net income (2) $1,364     $1,063     28.3 %   $10,563     $7,513     40.6 %                                   Adjusted EBITDA (1) (2) $2,051     $2,963     -30.8 %   $10,446     $16,210     -35.6 %                                   Basic EPS $0.28     $0.22     27.3 %   $2.15     $1.55     38.7 %Diluted...

WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023. “2023 was an exciting year for Mustang filled with many highlights, including compelling interim data from Mustang’s multicenter Phase 1/2 clinical trial of MB-106 presented at the 2023 American Society of Hematology Annual Meeting, which builds upon the stellar data presented earlier in the year from the MB-106 Phase 1/2 single institution clinical trial conducted at Fred Hutch. In both the multicenter...

– Delivered 2023 Gross Profit of $15.7 Million, Versus Gross Loss of $27.6 Million in 2022 – – Improved 2023 Net Loss by $13.6 Million and Adjusted EBITDA by $26.5 Million over 2022 – – Signed Letter of Intent with Vault 44.01 for CO2 Storage – PEKIN, Ill., March 11, 2024 (GLOBE NEWSWIRE) — Alto Ingredients, Inc. (NASDAQ: ALTO), a producer and distributor of renewable fuel and essential ingredients and the largest producer of specialty alcohols in the U.S., reported its financial results for the quarter and year ended December 31, 2023. For the fourth quarter of 2023, gross loss improved $18.8 million and Adjusted EBITDA improved $19.0 million over the fourth quarter of 2022. For the full year 2023, gross profit improved $43.2 million and Adjusted EBITDA improved $26.5 million over 2022. “During...

— 30th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 — — 1st patient dosed in CB-012 AMpLify Phase 1 trial for patients with r/r AML — — $372.4 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into Q1 2026 — BERKELEY, Calif., March 11, 2024 (GLOBE NEWSWIRE) —  Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the fourth quarter and full year 2023 and reviewed recent pipeline progress. “Following our execution in 2023, we enter 2024 with momentum advancing three clinical-stage off-the-shelf CAR-T cell therapy programs for patients with hematologic malignancies...

Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy and PAXTRAVA™ in Glaucoma Expected in Q2 2024 Cash Expected to Support Operations Into At Least 2028 Based on $196M YE 2023 Cash Balance Plus $325M Gross Proceeds from February 2024 PIPE Planning to Host an Investor Day in Q2 2024 to Outline Updated Corporate Strategy BEDFORD, Mass., March 11, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases...

–Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 2024– –Announced ongoing toxicology activities intended to support initiation of a potential proof-of-concept study of NGM120, a GDF15/GFRAL antagonist, for the treatment of hyperemesis gravidarum (HG) by the end of 2024– –Ongoing discussions with regulators on the design of a potential registrational trial of aldafermin, an engineered FGF19 analog, for the treatment of primary sclerosing cholangitis (PSC), a rare liver disease, using surrogate endpoints– –Reported $144.2 million in cash, cash equivalents and marketable...

Fourth quarter revenue increased 60% year-over-year to $44.9 million with Telehealth revenues increasing 90% versus the year-ago period. Adjusted EPS of $0.15 per share compared with $0.02 in the year-ago period. Consolidated adjusted EBITDA of $5.5 million compared with $1.0 million in the year-ago period. Weight Management subscribers exceeded 22,000 as of year-end 2023, ahead of previous guidance. Telehealth subscribers grew 27% year-over-year to a record 215,000 patients at year-end 2023.Conference call begins at 4:30 p.m. Eastern time today NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today reported financial results for the three and twelve months ended December 31, 2023.    Management Commentary “2023 was a record-setting year for LifeMD, characterized...

Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritized for further advancement towards registrational studies Initiation of combination study of ORIC-944 with AR inhibitor(s) in metastatic prostate cancer expected in first half of 2024 and program update expected in mid-2024 Initiation of multiple dose expansion cohorts for ORIC-114 in patients with mutated NSCLC expected in first half of 2024 and updated Phase 1b data expected in first half of 2025 Strengthened cash position with $210 million from two private placement financings; cash and investments expected to fund operating plan into late 2026 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology...

Company achieves record first quarter results with improved performance across all segments OXNARD, Calif., March 11, 2024 (GLOBE NEWSWIRE) — Mission Produce, Inc. (Nasdaq: AVO) (“Mission” or the “Company”), a world leader in sourcing, producing, and distributing fresh Hass avocados with additional offerings in mangos and blueberries, today reported its financial results for the fiscal first quarter ended January 31, 2024. Fiscal First Quarter 2024 Financial Overview:Total revenue increased 21% to $258.7 million compared to the same period last year driven primarily by a 23% increase in average per-unit avocado selling prices on flat avocado volumes Net income/(loss) was breakeven, or $0.00 per diluted share, compared to $(8.8) million, or $(0.12) per diluted share, for the same period last year Adjusted net income of $6.7 million,...